evipedia.ai
← Back

PEITC for Health & Longevity

Evidence Review created on 11/06/2026 using AI4L / Opus 5.5

Also known as: Phenethyl Isothiocyanate, Phenylethyl Isothiocyanate, 2-Phenethyl Isothiocyanate, 2-Phenylethyl Isothiocyanate, β-Phenylethyl Isothiocyanate, (2-isothiocyanatoethyl)benzene

Motivation

PEITC (phenethyl isothiocyanate) is a sharp-tasting plant compound released when watercress, horseradish and other cabbage-family vegetables are chopped or chewed. It draws interest from health-focused adults because it is thought to switch on the body’s own cleanup and defense systems and to act on how certain cancer-causing chemicals are processed, a proposed mechanism that has made it a candidate for cancer prevention and healthy aging.

Interest grew from decades of animal research on tobacco-related lung cancer and from population studies of people who eat many cabbage-family vegetables. Researchers have since tested it in small human studies: as a purified compound taken by smokers, as a watercress drink taken by mostly non-smoking adults, and as a fortified soft food eaten by people with advanced mouth cancer.

This review examines what is known about PEITC from human, animal and laboratory research: how it acts in the body, its expected benefits and potential risks, interactions with medicines, doses used in studies, sourcing, monitoring and open research questions, viewed through the lens of adults pursuing long-term health and longevity.

Benefits - Risks - Protocol - Conclusion

This section lists expert and academic overviews that discuss PEITC, its watercress source, or the isothiocyanate class in depth.

  • Watercress - Life Extension Editorial Staff

    Consumer-level overview of watercress as an exceptionally rich dietary source of the PEITC precursor and of the anticancer research behind it; Life Extension also sells supplements, a commercial interest.

  • Sulforaphane - Rhonda Patrick

    In-depth overview of sulforaphane, the best-studied isothiocyanate; it shares PEITC’s main mechanism, activation of Nrf2 (a master switch for the body’s antioxidant and detoxification genes).

  • Isothiocyanates: Translating the Power of Plants to People - Palliyaguru et al., 2018

    Narrative review of the human trials of PEITC and sulforaphane, written partly by investigators of the smoker trials, with discussion of food-based versus purified delivery.

  • Phenethyl isothiocyanate: a comprehensive review of anti-cancer mechanisms - Gupta et al., 2014

    Detailed catalogue of PEITC’s cell and animal anticancer targets, useful for understanding why the compound entered clinical testing.

  • RHR: The Powerful Health Benefits of Sulforaphane - Chris Kresser

    Podcast on sulforaphane’s Nrf2-driven detoxification that names PEITC, the watercress isothiocyanate, as boosting Nrf2 activation alongside sulforaphane; Kresser promotes a PEITC-containing supplement through an offer link, a commercial interest.

No directly relevant content was found from Peter Attia, Andrew Huberman or Lifespan.io: their on-site and web searches returned nothing on PEITC or watercress, and Huberman Lab and Lifespan.io mention sulforaphane only briefly within broader episodes or news roundups.

Grokipedia

Phenethyl isothiocyanate

AI-written encyclopedia entry covering PEITC’s chemistry, plant sources, formation from its precursor, and reported biological activities; useful as a quick orientation, not as primary evidence.

Examine

No Examine article on PEITC exists; the site’s search returns no PEITC page, only an unrelated entry for phenylethylamine.

ConsumerLab

No ConsumerLab article on PEITC exists; the site’s search returns no results for PEITC or phenethyl isothiocyanate.

Systematic Reviews

These systematic reviews cover PEITC directly or the dietary isothiocyanate sources and drug-metabolism effects that frame its benefits and risks.

Mechanism of Action

PEITC forms when myrosinase (a plant enzyme released by chewing or chopping) splits gluconasturtiin (its sulfur-containing precursor, abundant in watercress). It binds sulfur groups (thiols) on proteins, producing several effects (review: Dayalan Naidu 2018):

  • Defense-gene activation: PEITC modifies Keap1 (the protein that keeps Nrf2 inactive), freeing Nrf2 to turn on detoxification and antioxidant genes, and activates HSF1 (heat shock factor 1, a switch for protein-repair chaperones).
  • Carcinogen handling: it inhibits cytochrome P450 enzymes (liver and lung enzymes that oxidize drugs and toxins), including CYP2E1 and CYP2A13, which convert NNK (a tobacco-specific lung carcinogen) into DNA-damaging forms, and it boosts phase II enzymes (enzymes that attach water-soluble tags to toxins for excretion) (review: Ioannides 2015; Nakajima 2001).
  • Cancer-cell stress: at higher concentrations it depletes glutathione (the cell’s main antioxidant) and raises reactive oxygen species (ROS, unstable oxygen molecules), triggering apoptosis (programmed cell death) in cancer cells (review: Gupta 2014).

A competing view holds that the same Nrf2 activation could shield established tumors from oxidative stress and treatment (review: Malavolta 2018).

Pharmacology: PEITC is fat-soluble, highly protein-bound and non-selective. It is conjugated to glutathione by glutathione S-transferases (GSTs, including the products of the GSTM1 and GSTT1 genes, which many people lack) and excreted in urine as an N-acetylcysteine conjugate; efflux transporters BCRP and MRP1/2 (cell-membrane pumps that expel compounds) move it across tissues (review: Morris 2014). Half-life was 2.4 hours in an earlier phase I (first-in-human dose-finding) study, as reported secondhand in a later smoker trial (Yuan 2016).

Historical Context & Evolution

PEITC was never developed for a medical use; it is a natural constituent of watercress, horseradish and other cabbage-family vegetables eaten for centuries as foods and condiments.

Scientific interest began in 1977, when Wattenberg showed that PEITC and related isothiocyanates given before or together with a carcinogen inhibited mammary, forestomach and lung tumors in rodents (Wattenberg 1977). In 1989, researchers at the American Health Foundation reported that dietary PEITC halved NNK-induced lung tumors and lung DNA damage in rats, though liver and nasal tumors were unaffected (Morse 1989). This tobacco-carcinogen model made PEITC a lead candidate for preventing lung cancer in smokers.

Human work followed: watercress raised urinary NNK detoxification products in smokers (Hecht 1995), and urinary isothiocyanates predicted lower lung cancer risk in Shanghai men (London 2000). Countervailing animal data emerged at the same time: high dietary PEITC promoted bladder tumors in rats (Hirose 1998), showing that the compound can also harm at high intakes.

Randomized trials in smokers then found modest but statistically significant shifts in carcinogen metabolism (Yuan 2016). Interest has since broadened to fortified foods in cancer patients, tested in a trial sponsored by the Dental Innovation Foundation, which supplied the jelly and ran its earlier pharmacokinetic study (NCT03700983), a conflict of interest (Lam-Ubol 2023), and to watercress drinks for environmental toxicants (Hecht 2025). The open question is no longer whether PEITC changes carcinogen handling in people, but whether those changes translate into fewer cancers or longer healthy life.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only clinical-endpoint trial of PEITC comes from a single research group, and the other human data are urinary carcinogen-metabolite biomarkers, observational studies of total dietary isothiocyanates, or whole-watercress studies.

Medium 🟩 🟩

Disease Stabilization and Quality of Life in Advanced Oral Cancer ⭕️ Not Central to Health & Longevity

In a placebo-controlled trial by a single Thai research group (Lam-Ubol, Trachootham), 72 people with advanced mouth or throat cancer ate jelly with or without 20 mg PEITC five days a week for 12 weeks (Lam-Ubol 2023). The PEITC group had longer progression-free survival (time until the tumor grew) and more participants with improved head-and-neck quality-of-life scores. Groups were unequal (31 versus 41) and dropout was high. Cell and rodent data show similar activity (review: Gupta 2014). The result bears on cancer care, not on prevention in healthy adults.

Magnitude: Mean progression-free survival 7.37 ± 4.45 weeks versus 4.93 ± 4.15 weeks with placebo jelly (no 95% CI, or confidence interval, the range likely to contain the true effect, reported); stable disease or partial response at 3 months 50% versus 20% (Lam-Ubol 2023).

Low 🟩

Lower Lung Cancer Risk ⚠️ Conflicted

Evidence is indirect: studies measured total urinary isothiocyanates or cruciferous intake, not PEITC. Detectable urinary isothiocyanates predicted lower risk, mainly in GSTM1/GSTT1-null men (London 2000). A systematic review found lower risk in patient-versus-control studies but not in studies following people forward (Lam 2009). Net: a weak, genotype-dependent association.

Magnitude: Relative risk (risk with exposure divided by risk without) 0.65 (95% CI 0.43–0.97) for detectable versus undetectable urinary isothiocyanates (London 2000); pooled relative risk 0.83 (95% CI 0.62–1.08) in studies following people forward, for highest versus lowest cruciferous intake (Lam 2009).

Speculative 🟨

Enhanced Detoxification of Tobacco and Environmental Carcinogens ⚠️ Conflicted

In smokers, 40 mg/day raised benzene and acrolein detoxification but not crotonaldehyde (Yuan 2016); watercress raised both (Hecht 2025). Butadiene detoxification did not rise significantly overall (Boldry 2020). Net: selective gains on unvalidated biomarkers.

Reduced DNA Damage in Blood Cells

Eating 85 g raw watercress daily for 8 weeks lowered lymphocyte DNA strand breaks (Gill 2007). Evidence is indirect (whole watercress), and the comet assay (a single-cell DNA-break test) is an unvalidated marker.

Improved Antioxidant and Inflammation Markers ⚠️ Conflicted

Seven randomized watercress trials improved most antioxidant and inflammation markers (review: Wen 2025); purified PEITC changed neither in smokers (Yuan 2016). Net: whole watercress (indirect) improves these unvalidated markers; purified PEITC does not.

Lower Body Fat and Liver Fat

In mice fed a high-fat diet, PEITC lowered body weight, fat mass and liver triglycerides (Chuang 2019). No human data exist; the basis is animal work only.

Benefit-Modifying Factors

  • GSTM1/GSTT1 genotype: Smokers lacking both genes had a 95.4% rise in benzene detoxification with PEITC, versus no effect in carriers of both genes (Yuan 2016); the epidemiologic lung cancer association was also strongest in double-null men (London 2000).
  • Baseline biomarker and exposure levels: Effects were measured mainly in people with high carcinogen exposure; watercress lowered DNA damage more in smokers than non-smokers (Gill 2007), though a mostly non-smoking cohort still showed raised detoxification markers (Hecht 2025).
  • Sex: Inhibition of NNK activation was numerically stronger in women, but the interaction test (a check of whether the effect truly differs between groups) was not statistically significant (Yuan 2016); no sex-specific clinical outcome data exist.
  • Pre-existing conditions: The oral cancer benefit was reported in tumors where p53 (a tumor-suppressor protein) is often mutated (Lam-Ubol 2023); in cells, the type of p53 mutation determined sensitivity to PEITC (Aggarwal 2019).
  • Age: Smokers aged 40 or older showed a numerically stronger effect on NNK activation, not statistically significant (Yuan 2016). No trial has enrolled adults at the older end of the target range.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal and Oral Irritation

In smokers taking 40 mg/day, adverse events were mild gastrointestinal complaints (dry mouth, altered taste, abdominal pain, belching, flatulence, diarrhea), none severe (Yuan 2016; Yuan and Hecht group, Minnesota). In the independent Thai trial (Lam-Ubol and Trachootham group), nausea, vomiting and mouth burning were more frequent with PEITC jelly than placebo (Lam-Ubol 2023). A placebo-controlled watercress-drink trial (about 40 mg/day) recorded more nausea, stomach pain and oral burning, with no serious events (NCT03978117). An earlier phase I study, reported secondhand (Yuan 2016), found more distress at 120 than 40 mg/day.

Magnitude: Nausea and vomiting 22.6% versus 9.8% with placebo jelly; mouth burning 16.1% versus 9.8% (Lam-Ubol 2023); with the watercress drink, nausea in 30 of 300 versus 5 of 300 and oral burning or tingling in 21 versus 1 of 300 with placebo drink, as posted results (NCT03978117); in the purified-PEITC smoker trial, gastrointestinal adverse events in 62 of 107 during PEITC versus 30 of 107 during placebo, as posted results (NCT00691132); the published report named event types without rates (Yuan 2016).

Medium 🟥 🟥

No risk reaches Medium: beyond gastrointestinal effects, human harm data come only from whole-watercress pharmacokinetic studies, and the remaining concerns rest on rodent or cell experiments.

Low 🟥

Altered Metabolism of Co-Administered Drugs ⚠️ Conflicted

A single 50 g watercress serving inhibited CYP2E1: chlorzoxazone exposure rose (Leclercq 1998) and acetaminophen’s oxidative metabolites fell (Chen 1996). A randomized crossover trial (each volunteer tested every condition) found no major change in ethanol clearance (Desager 2002). Evidence is indirect (watercress, not purified PEITC). Net: effects are drug-specific.

Magnitude: Chlorzoxazone AUC (total drug exposure over time) rose 56% and half-life 53% versus the same volunteers’ baseline, no control group (Leclercq 1998); plasma cysteine-acetaminophen AUC fell 28% versus acetaminophen alone (Chen 1996).

Speculative 🟨

Bladder Tumor Promotion at High Intakes

In rats, diets above 0.01% PEITC promoted chemically started bladder tumors, and 0.05–0.1% alone caused bladder overgrowth (Hirose 1998, Ogawa 2001). Basis is animal work only, at doses well above human intakes.

Protection of Established Tumors

Nrf2 activation may help existing cancer cells resist oxidative stress and treatment, a concern raised for Nrf2-activating plant compounds including PEITC (review: Malavolta 2018). Basis is mechanistic only.

Thyroid Disruption ⚠️ Conflicted

Isothiocyanates are suspected of competing with thyroid iodine uptake. A systematic review found no adverse thyroid effect of cabbage-family vegetables with adequate iodine (Galanty 2024). Net: the concern is theoretical.

Risk-Modifying Factors

  • GSTM1/GSTT1 genotype: Smokers lacking these genes excreted more PEITC metabolites, a pattern the authors could not explain (Yuan 2016); no difference in side effects by genotype has been reported.
  • Baseline liver function: Trials enrolled adults with normal liver tests (Yuan 2016), and blood chemistry did not change over 3 months (Lam-Ubol 2023); behavior with impaired liver clearance is unstudied.
  • Sex: No sex differences in adverse events have been reported; no safety data exist for pregnancy or breastfeeding.
  • Pre-existing conditions: Bladder disease (rat promotion data), upper gastrointestinal disorders (irritation), low iodine intake (thyroid concern) and multi-drug regimens cleared by CYP2E1, CYP2C9 or CYP1A2 (liver enzymes that clear many common drugs) plausibly raise risk; none has been tested in humans.
  • Age: Older adults more often take several medications cleared by cytochrome P450 enzymes, raising interaction potential; no trial has reported age-specific adverse event rates.

Key Interactions & Contraindications

Documented interactions:

  • CYP2E1 substrates (chlorzoxazone, enflurane): 50 g watercress raised chlorzoxazone exposure 56%, risking stronger sedation (Leclercq 1998); separating watercress or PEITC intake from dosing days lowers exposure change.
  • Acetaminophen (paracetamol): Watercress cut oxidative acetaminophen metabolites, the pathway producing its liver-toxic intermediate, without changing acetaminophen levels (Chen 1996); the single-dose study described no mitigating action.
  • Ethanol: No meaningful interaction found on ethanol clearance; watercress delayed alcohol absorption and possibly raised peak acetaldehyde, a flushing-related metabolite (Desager 2002).
  • Coumarin: No meaningful interaction found: watercress at most marginally delayed coumarin breakdown by CYP2A6 (a liver enzyme that also clears nicotine) in 15 volunteers (Murphy 2001); no mitigating action is needed.
  • Nicotine (cigarettes, nicotine replacement): Purified PEITC raised 3′-hydroxycotinine glucuronidation (attachment of a sugar tag for excretion) and borderline raised urinary nicotine (Yuan 2016); watercress raised cotinine glucuronides (Hecht 1999); clinical consequence is minor and no dose change is described.
  • CYP1A2 substrates (caffeine, theophylline, clozapine): A meta-analysis of cruciferous-rich diets, including watercress, found CYP1A2 activity raised 20–40%, which could lower exposure to drugs it clears (Eagles 2020); keeping intake consistent and checking theophylline or clozapine levels limits swings.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • CYP2C9 and CYP2B6 substrates (warfarin, phenytoin; bupropion, efavirenz): Inferred from strong in vitro inhibition of these drug-clearing liver enzymes (Nakajima 2001); consequence could be higher drug levels and, with warfarin, bleeding. INR (clotting-time test) checks after starting limit this.
  • CYP2C19 and CYP3A4 substrates (omeprazole, clopidogrel; simvastatin, midazolam): Inferred from weaker in vitro inhibition of these drug-clearing enzymes (Nakajima 2001); consequence could be higher drug exposure or reduced clopidogrel activation. Watching for drug-specific side effects limits this.
  • Chemotherapy relying on oxidative stress (doxorubicin, cisplatin): Inferred from glutathione depletion and mouse data showing altered doxorubicin effects (Eisa 2015); consequence could be changed efficacy or toxicity. Disclosure to the treating oncologist allows coordination.
  • Other Nrf2-activating supplements (sulforaphane, broccoli sprout extract, curcumin): Inferred from shared Nrf2 and phase II enzyme induction; consequence could be additive effects on drug metabolism. Introducing one agent at a time isolates effects.
  • Thiol antioxidants (N-acetylcysteine, glutathione): Inferred from PEITC’s thiol reactivity (review: Dayalan Naidu 2018); consequence could be neutralization of PEITC’s oxidative-stress effects. Separating doses by several hours reduces direct binding.
  • BCRP and MRP transporter substrates (methotrexate, rosuvastatin): Inferred from shared efflux transport (review: Morris 2014); consequence could be raised drug levels. Monitoring drug-specific toxicity limits this.

Populations who should avoid PEITC:

  • Pregnancy and breastfeeding: Inferred from the absence of any human safety data and PEITC’s reactive chemistry; no human data.
  • Bladder cancer or precancerous bladder lesions: Inferred from bladder tumor promotion in rats (Hirose 1998); no human data.
  • Users of narrow-margin CYP2C9 drugs (warfarin, phenytoin) for purified high-dose PEITC: Inferred from in vitro enzyme inhibition (Nakajima 2001); no human data.
  • Known allergy to mustard, horseradish or wasabi isothiocyanates: Inferred from shared isothiocyanate chemistry; no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Intake within studied doses: Prevents dose-related gastrointestinal distress; 40 mg/day was tolerated, while 120 mg/day caused more distress in an earlier phase I study, as reported secondhand in the smoker trial (Yuan 2016).
  • Intake with food or oil: Reduces gastrointestinal discomfort and mouth irritation; trial doses were delivered in 1 mL olive oil (Yuan 2016).
  • Food sources over purified compound: Limits exposure to the high intakes linked to rat bladder tumor promotion; watercress delivers PEITC within studied ranges (Hecht 1995).
  • Medication review before starting: Prevents altered drug levels with CYP2E1, CYP2C9 or CYP1A2 drugs; for warfarin users, common practice is an INR check within 1–2 weeks of starting.
  • Consistent daily intake: Limits swings in drug exposure from fluctuating enzyme activity, which a meta-analysis of diet trials suggests large or variable intake can cause (Eagles 2020).
  • Periodic urinalysis with long-term purified use: Detects blood in urine early, addressing the rat bladder-promotion concern; every 6–12 months.
  • Adequate iodine intake: Mitigates the theoretical thyroid concern, based on the review linking safety to iodine sufficiency (Galanty 2024).
  • Pausing with persistent symptoms: Limits gastrointestinal harm; use is commonly stopped when nausea or vomiting lasts more than a few days.

Therapeutic Protocol

Parameters without a citation (timing, splitting, titration) reflect common practice.

  • Purified PEITC (research protocol): 10 mg in 1 mL olive oil four times daily, 40 mg/day, for 1 week, used by the Hecht and Yuan group in smokers (Yuan 2016).
  • Higher-dose phase I range: Up to 120 mg/day for 30 days in an earlier phase I study, with more gastrointestinal distress than 40 mg/day, as reported secondhand in the smoker trial (Yuan 2016).
  • Fortified food: 20 mg PEITC in 200 g jelly, five days a week for 12 weeks, the Trachootham group’s approach in oral cancer (Lam-Ubol 2023).
  • Raw watercress: 56.8 g at each of three meals, about 19–38 mg PEITC daily (Hecht 1995); 85 g daily in a DNA-damage study (Gill 2007).
  • Freeze-dried watercress drink: Three times daily, about 40 mg PEITC daily, for 2 weeks (Hecht 2025); popularized by the University of Minnesota group, which calls watercress the more acceptable delivery form (Yuan 2016).
  • Competing approaches: Purified compound and whole watercress have each been studied at roughly 40 mg/day; no trial compares them head to head, and Life Extension, which sells supplements, promotes the food route (Life Extension Watercress article).
  • Time of day: With meals, since PEITC is fat-soluble and irritant on an empty stomach.
  • Half-life: About 2.4 hours in the phase I study, as reported secondhand in the smoker trial (Yuan 2016); urinary metabolite levels at 120 mg/day kept rising for 2 weeks.
  • Single versus split dosing: Split doses three to four times daily keep levels steadier, matching trial schedules.
  • Genetic polymorphisms: GSTM1/GSTT1 double-null individuals showed the largest detoxification effects (Yuan 2016); genotyping identifies likely stronger responders.
  • Sex: No sex-specific dosing exists; effect differences by sex were not statistically significant (Yuan 2016).
  • Age: No age-specific dosing; older adults on several medications typically start with food sources.
  • Baseline biomarker levels: Response was studied in people with measurable carcinogen exposure (smokers, urban air); low-exposure individuals may see smaller biomarker changes.
  • Pre-existing conditions: Trials enrolled people with normal liver function; bladder disease and gastrointestinal disorders favor food sources over purified compound.

Discontinuation & Cycling

  • Lifelong versus short-term: Trials lasted 1 to 12 weeks; long-term purified use is unstudied, whereas watercress as food is eaten indefinitely.
  • Withdrawal effects: None reported; urinary carcinogen-metabolite changes returned to near baseline within 1–2 weeks after watercress stopped (Hecht 1995).
  • Tapering: Not required, as no withdrawal or rebound effects have been described.
  • Cycling: Not studied; no tolerance has been reported, and crossover trials used 1-week washouts (breaks between treatments) without carryover effects (lingering effects of the earlier treatment) (Yuan 2016).

Sourcing and Quality

  • Purified PEITC: Mostly sold as a laboratory reagent; food-grade PEITC was used to fortify the Thai trial jelly (Lam-Ubol 2023); smoker-trial material was purified to 99.2% under good manufacturing practice for a U.S. Food and Drug Administration (FDA) investigational permit (Yuan 2016).
  • Fresh watercress: The richest food source; PEITC is volatile and lost quickly once tissue is crushed, so raw watercress eaten soon after chopping or chewing delivers most (Rose 2000).
  • Freeze-dried watercress: Produced at industrial scale with validated food safety for the Minnesota trial, in partnership with a watercress grower and food companies, an industry involvement noted here (Bonorden 2022).
  • Extracts and capsules: Watercress or cruciferous extract products rarely state PEITC or gluconasturtiin content; a certificate of analysis and third-party testing (United States Pharmacopeia or NSF International seals) indicate quality.
  • Reputable brands: Some sulforaphane capsules add PEITC (e.g., BrocElite, promoted by Chris Kresser in his Kresser podcast), but no commercial PEITC product has clinical data; Nutri-PEITC Jelly has been used only in Thai trials.

Practical Considerations

  • Time to effect: Carcinogen-metabolite changes appeared within 2–3 days of watercress (Hecht 1995); oral cancer outcomes were assessed at 1 and 3 months (Lam-Ubol 2023).
  • Common pitfalls: Cooking watercress, which inactivates myrosinase; swallowing undiluted reagent-grade PEITC; and assuming that biomarker changes prove lower cancer risk or longer life.
  • Regulatory status: Purified PEITC has been used in humans only as an investigational agent; the smoker trials ran under an FDA investigational new drug permit (IND 74,037) (Yuan 2016). Watercress is sold as an ordinary vegetable.
  • Cost and accessibility: Watercress is inexpensive and widely sold (Bonorden 2022); purified PEITC is mainly a laboratory reagent, appearing in supplements only as an add-in to sulforaphane capsules, which makes food the accessible route.
  • Lifespan evidence gap: No study has tested PEITC on lifespan in any organism.

Interaction with Foundational Habits

  • Sleep: None known; no study has measured sleep, and the short half-life (phase I data reported secondhand in Yuan 2016) means evening doses are unlikely to persist overnight, though gastrointestinal discomfort could disturb sleep in sensitive people.
  • Nutrition: Direct and potentiating; raw cabbage-family vegetables supply PEITC and related isothiocyanates, while cooking reduces release. Watercress also adds carotenoids such as lutein (Gill 2007). Taking PEITC with dietary fat matches trial delivery in olive oil.
  • Exercise: Indirect and possibly blunting; watercress before exhaustive exercise reduced exercise-induced DNA damage and lipid oxidation (Fogarty 2013). Whether dampening this oxidative signal blunts training adaptation is untested; separating intake from training sessions is a common precaution.
  • Stress management: Indirect; PEITC activates heat-shock stress-defense programs in cells (review: Dayalan Naidu 2018), but no human study has measured cortisol, perceived stress or psychological outcomes.

Monitoring Protocol & Defining Success

Baseline testing before starting purified PEITC covers liver enzymes, a urinalysis for blood, and, for warfarin users, a clotting-time test, so that later changes can be judged against personal values. Optional GSTM1/GSTT1 genotyping helps interpret response, because double-null individuals showed the largest detoxification shifts. Watercress eaten as food in normal amounts needs no special testing.

Ongoing monitoring follows a cadence of liver enzymes at 4–8 weeks, then every 6–12 months during continued purified use; urinalysis every 6–12 months; and INR within 1–2 weeks of starting or changing dose for warfarin users. Success is defined modestly: good tolerance, stable laboratory values and, where research testing is available, higher urinary PEITC metabolite levels confirming intake. No clinical test can show reduced cancer risk.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT and AST ALT 7–55 U/L; AST 8–48 U/L (standard reference range) Safety check: rises would stop or change use ALT and AST are liver enzymes released by damaged liver cells; trials enrolled normal liver function (Yuan 2016); no fasting needed
Urinalysis for blood Negative for blood (standard reference range) Safety check: blood in urine would stop use Addresses the rat bladder-promotion signal (Ogawa 2001); first-morning sample preferred
INR (warfarin users only) No established target for PEITC; track change from the individual’s stable baseline Safety check: a rise would change warfarin dosing INR (international normalized ratio) measures clotting time; concern inferred from CYP2C9 inhibition (Nakajima 2001)
Urinary PEITC-NAC No established target; track change from the individual’s own baseline Expected to change: confirms intake and absorption PEITC-NAC (PEITC–N-acetylcysteine conjugate) is the main urinary metabolite; research assay only; about 29% of a dose appears in urine (Yuan 2016); 24-hour collection preferred

Qualitative markers:

  • Gastrointestinal comfort (nausea, abdominal pain, belching, diarrhea)
  • Mouth sensations (burning, dryness, altered taste)
  • Energy and general well-being
  • Adherence to the planned dose and schedule

Emerging Research

  • CRUCIAL-R cruciferous diet trial (NCT07391137): 250 people with non-muscle-invasive bladder cancer, randomized to a high-cruciferous diet or usual diet; primary endpoint 1-year recurrence-free survival; active, completion May 2027. A positive result would strengthen the dietary isothiocyanate case; a null result would weaken it and temper bladder-related hopes.
  • Watercress during radiotherapy (NCT02468882): 200 cancer patients receiving 100 g watercress daily during radiation; phase 3; registered completion January 2019 passed, status unknown, no results posted.
  • PEITC and mutant p53 in smokers’ oral cells (NCT01790204): 55 participants drinking watercress juice; completed April 2014, no results posted; results would test the mutant-p53 mechanism in humans.
  • Watercress drink detoxification trial (NCT03978117): Completed November 2024; results published, showing raised detoxification of six of seven toxicants (Hecht 2025), cited under benefits; posted adverse events, mainly mild gastrointestinal and oral, with none serious, are cited under risks.
  • Nutri-PEITC Jelly trial (NCT03034603): Completed January 2023; results published (Lam-Ubol 2023), cited under benefits and risks.
  • Genotype-guided prevention: Effects concentrated in GSTM1/GSTT1-null smokers (Yuan 2016, Boldry 2020) suggest stratified trials could strengthen or, if unconfirmed, weaken the case.
  • Long-term safety: Rat bladder promotion (Ogawa 2001) has no human counterpart study; long-term human data could either dispel or confirm this risk.
  • New targets: PEITC restored function of misfolded alpha-1 antitrypsin (a lung-protecting protein) in cell models (Sun 2025), an untested human application.

Conclusion

Phenethyl isothiocyanate is a natural compound from watercress and related vegetables that switches on the body’s detoxification and defense systems and slows the activation of some tobacco and environmental cancer-causing chemicals. For health-focused adults, its appeal is a food-derived way to lower the burden of everyday carcinogens.

The human evidence is real but narrow. Small, well-controlled studies in smokers and in mostly non-smoking adults show that the compound, whether purified or from watercress, changes how the body handles certain toxins, with larger effects in people who naturally lack two detoxifying genes. Whether these chemical shifts lower cancer rates or extend healthy life has never been tested. A single trial in people with advanced mouth cancer reported slower disease progression and better quality of life, but it was small, was run by the product’s own sponsor, and does not apply to healthy adults. Population studies linking these vegetable compounds to lower lung cancer risk are weak and inconsistent. The watercress drink in the largest trial was produced with food-industry partners, and two expert sources discussed here sell or promote supplements.

At studied amounts, side effects are mostly mild stomach and mouth irritation. The main practical risk is altered handling of some medications. Rat studies showing bladder harm at high intakes, and the possibility of protecting existing tumors, remain unconfirmed in people.

Overall, the evidence supports the compound as a plausible, low-cost add-on through food, with uncertain long-term value and limited information on purified, long-term use.

Top - Benefits - Risks - Protocol